You are here

  • Home
  • Archive
  • Volume 28, Issue 4
  • Safety and Efficacy of Extended Bevacizumab Therapy in Elderly (≥70 Years) Versus Younger Patients Treated for Newly Diagnosed Ovarian Cancer in the International ROSiA Study

Article metrics

Article menu
Download PDFPDF
Ovarian Cancer
Safety and Efficacy of Extended Bevacizumab Therapy in Elderly (≥70 Years) Versus Younger Patients Treated for Newly Diagnosed Ovarian Cancer in the International ROSiA Study

 

Online download statistics by month:

Online download statistics by month: February 2019 to September 2024

AbstractFullPdf
Feb 2019400
Mar 20193501
Apr 20194001
May 20197601
Jun 20195601
Jul 20196004
Aug 20195202
Sep 20196701
Oct 20195300
Nov 20193001
Dec 20195701
Jan 20206602
Feb 20207600
Mar 20207001
Apr 20205500
May 20204500
Jun 20205403
Jul 20204600
Aug 20202800
Sep 20202901
Oct 20201500
Nov 20204200
Dec 20202500
Jan 20213501
Feb 20215300
Mar 20217001
Apr 20212800
May 20211001
Jul 2021100
Aug 2021001
Sep 2021100
Oct 20213100
Nov 20214401
Dec 20211700
Jan 20223400
Feb 20222801
Mar 20225602
Apr 20225702
May 20227802
Jun 20226000
Jul 202210800
Aug 20228500
Sep 20227101
Oct 20226201
Nov 202210102
Dec 20224501
Jan 202312300
Feb 202316204
Mar 20234000
Apr 20232600
May 20236101
Jun 20234902
Jul 20233201
Aug 20235801
Sep 20233900
Oct 20233100
Nov 20239700
Dec 20236000
Jan 20249502
Feb 20243902
Mar 20243700
Apr 20244001
May 20245300
Jun 20247202
Jul 20246900
Aug 20246301
Sep 20243600
Total3438054